A phase I, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of ADCT-601 in patients with advanced solid tumours

Category Primary study
JournalAnnals of Oncology
Year 2019
This article has no abstract
Epistemonikos ID: 2ae35f850920130b594251540e2a35f4803180d0
First added on: Feb 11, 2025